Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Kyowa Kirin
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Kyowa Kirin Taps Synaffix ADC Technology to Expand Its Pipeline
Details : Synaffix will provide all proprietary ADC technologies, including GlycoConnect™, HydraSpace™, and select toxSYN™ linker-payloads. Kyowa Kirin will leverage its innovative antibody-based therapeutics pipeline to develop a portfolio of ADCs with opti...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 08, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Kyowa Kirin
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Immunomedics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
ProteoNic Announces Licensing of Technology for Production of Biologics to Immunomedics
Details : Under the agreement, Immunomedics gains commercial rights for application of ProteoNic’s technology platform to the development of specified proprietary products from mammalian cells.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
October 20, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Immunomedics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : ADC Therapeutics
Deal Size : $54.0 million
Deal Type : Collaboration
Synaffix Announces Expansion of Collaboration with ADC Therapeutics
Details : Under the expanded collaboration, ADC Therapeutics has been granted non-exclusive rights for two additional programs, which brings the total number of programs using Synaffix’ ADC technologies to five.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 23, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : ADC Therapeutics
Deal Size : $54.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Shanghai Miracogen
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Miracogen has been granted non-exclusive rights to Synaffix’s proprietary GlycoConnect™ and HydraSpace™ ADC technologies for use in this second clinical candidate.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 01, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Shanghai Miracogen
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : ProBioGen
Deal Size : Undisclosed
Deal Type : Agreement
ProBioGen, Lava Therapeutics Sign Cell Line Mfg. Pact
Details : Under the agreement and using its CHO.RiGHT™ expression platform, ProBioGen will conduct cell line development of a ?? T-cell engaging bispecific antibody format.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 14, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : ProBioGen
Deal Size : Undisclosed
Deal Type : Agreement